Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A platform partnership
January 2020
SHARING OPTIONS:

SCHLIEREN, Switzerland & SAN FRANCISCO—Late last year, Akero Therapeutics selected InSphero AG’s 3D InSight Human Liver Disease platform to characterize AKR-001’s physiological effects in different kinds of liver cells. This effort will evaluate AKR-001’s effects on liver metabolism, NASH-induced liver fibrosis, and pathways related to stress and cell death of hepatocytes, among other effects. AKR-001 is a novel, long-acting FGF21 analog being developed for the treatment of NASH.
 
“We believe AKR-001 has unique potential among investigational NASH therapies to restore whole-body metabolic balance while also acting directly to reduce inflammation and fibrotic scarring in the liver,” commented Tim Rolph, chief scientific officer and co-founder of Akero. “With InSphero’s human in-vitro liver disease platform, we will evaluate AKR-001’s effects on human liver cells to help contextualize results from our ongoing Phase 2a clinical trial.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.